🤖 Generated with AI assistance · Does not replace individualized medical advice.
AI Act Transparency Notice
This content was generated with the assistance of artificial intelligence to summarize and structure scientific literature. It is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare provider for personal medical decisions.
Predicting Neoadjuvant Response in Esophageal Cancer: A Graph-Based Multimodal Mamba Model
Key Facts
| Metric | Value | Context |
|---|---|---|
| Internal Validation AUC | 0.802 | Discriminative ability in the training institution cohort PMID: 42771946. |
| External Validation AUC | 0.740 | Generalizability performance in an independent cohort PMID: 42771946. |
| Study Population | 274 Patients | Retrospective cohort of ESCC patients receiving NICT PMID: 42771946. |
| Model Architecture | Graph-Based Mamba | Integrates radiomics, deep features, and clinical variables via graph modeling PMID: 42771946. |
Why It Matters / Context
Neoadjuvant immunochemotherapy (NICT) has emerged as a standard-of-care approach for locally advanced esophageal squamous cell carcinoma (ESCC), offering the potential to downstage tumors and improve long-term survival. However, a significant subset of patients does not achieve a pathological complete response (pCR) or major pathological response (MPR), exposing them to the toxicity of chemotherapy and immunotherapy without proportional benefit. Conversely, patients who are resistant to NICT may require alternative strategies, such as definitive chemoradiation or immediate surgery, depending on institutional protocols.
The challenge lies in the heterogeneity of tumor biology and the limitations of current predictive tools. Traditional clinical variables (e.g., tumor stage, performance status) lack sufficient granularity to predict individual response. While radiomics and deep learning models have shown promise, they often struggle with the complex, non-linear relationships between imaging features and clinical outcomes. Furthermore, most existing models treat modalities in isolation or use simple concatenation, failing to capture the intricate cross-modal interactions that drive tumor behavior.
The GBMM addresses these gaps by leveraging the Mamba architecture, a state-space model known for its efficiency in processing long sequences, combined with graph neural networks. This approach allows the model to treat different data modalities (clinical, radiomic, deep image features) as nodes in a graph, facilitating the learning of complex dependencies between, for example, systemic inflammatory markers and local tumor texture. This represents a shift from “feature stacking” to “relational learning” in oncology AI.
Details
The study enrolled 274 patients with ESCC who underwent NICT, split into training, internal validation, and external validation cohorts. The GBMM framework integrated four key components:
1. Clinical Features: Demographics, lab values, and staging.
2. Radiomics Features: Quantitative texture and shape metrics extracted from pretreatment CT scans.
3. Deep Image Representations: High-level features extracted via convolutional neural networks.
4. Expert Annotations: Structured data points provided by radiologists.
These components were fused using graph modeling and cross-modal interaction mechanisms. The Mamba-based representation learning module processed the integrated features, while a teacher-student knowledge accrual strategy was employed to enhance model robustness.
Performance was evaluated against state-of-the-art (SOTA) competing multimodal models. The GBMM demonstrated superior discriminative ability, achieving an AUC of 0.802 in the internal validation cohort and 0.740 in the external validation cohort PMID: 42771946. These results were statistically better than those of the competing models, suggesting that the graph-based integration of multimodal data provides a meaningful advantage over conventional fusion techniques.
Decision curve analysis (DCA) further supported the clinical utility of the model, showing a positive net benefit across a broad range of threshold probabilities. This indicates that using GBMM to guide treatment decisions would result in better patient outcomes compared to a “treat all” or “treat none” strategy within the tested probability ranges.
Interpretability was assessed using Shapley Additive Explanations (SHAP). The analysis highlighted several key predictive factors:
- Tumor Texture and Morphology: Imaging features reflecting heterogeneity and shape irregularity.
- Systemic Inflammatory Status: Likely represented by markers such as the neutrophil-to-lymphocyte ratio (NLR) or C-reactive protein (CRP).
- Physiological Reserve: Indicators of the patient’s overall health and ability to tolerate treatment.
- Regional Disease Burden: The extent of nodal involvement or local invasion.
These findings align with current oncological understanding, where systemic inflammation and tumor microenvironment characteristics are known to influence immunotherapy response.
Limitations
Critical Appraisal:
* Retrospective Design: The study is retrospective, introducing potential selection and information biases.
* Sample Size: The cohort of 274 patients is relatively small for training complex deep learning models, increasing the risk of overfitting, despite the use of external validation.
* Single-Modality Imaging: The model relies solely on CT imaging. The absence of PET-CT or MRI data may limit the capture of metabolic and functional tumor characteristics.
* Lack of Prospective Validation: The authors explicitly state that further validation on larger multicenter prospective cohorts is required before clinical utility can be established.
* Generalizability: External validation was performed, but the specific characteristics of the external cohort (e.g., different scanner types, NICT regimens) are not detailed in the abstract, making it difficult to assess the true breadth of generalizability.
Clinical Takeaway
While not yet ready for routine clinical deployment, the GBMM framework suggests that integrating graph-based multimodal learning with Mamba architectures can significantly improve the prediction of neoadjuvant response in ESCC, warranting prospective multicenter trials to validate its utility in guiding personalized treatment selection.
Full Reference
Zhang X, Peng P, Chen J, Wu W, Wu Y, Zheng G. GBMM: A graph-based multimodal Mamba model for response prediction in patients with esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy. International Journal of Medical Informatics. 2026. PMID: 42771946 [DOI: 10.1016/j.ijmedinf.2026.106734]